US Israel Gefen Capital Management

Gideon Saar personally directs all investment decisions, drawing on his experience building and exiting Gefen Biomed Investments on the Tel Aviv Stock Exchange. Saar's investment committee operates with support from an external scientific advisory panel that includes researchers from Tel Aviv Sourasky Medical Center and Technion — Israel Institute of Technology. His background as a former Israeli cabinet minister and MK adds a distinct regulatory and policy perspective to deal evaluation, though the firm does not invest in government-related ventures.

The firm targets late-stage Israeli life-science companies with clear regulatory pathways, alongside seed-stage medical device and diagnostics startups emerging from Israeli universities. Geographically, the focus is concentrated on Israel's Herzliya and Haifa innovation corridors, with selective co-investments in US-based companies that maintain active Israeli R&D operations. The firm participates exclusively through direct equity positions and structured co-investments, avoiding fund commitments.

Gefen Capital has historically avoided pure-play software and consumer internet investments, focusing instead on regulated medical products, diagnostics, and life-science platforms requiring FDA or CE-mark approval. The firm also does not invest in defense technology or cybersecurity — sectors where many Israeli family offices concentrate — reflecting Saar's deliberate separation of his investment activity from his prior government portfolio. Energy and agri-food-tech investments are pursued only where clear crossover with health-sensing technologies exists.